How long should you be on tirzepatide — and what does the evidence say?

What 72 weeks of trial data actually showed about timing

The foundational evidence comes from SURMOUNT-1, published in the New England Journal of Medicine, which followed over 2,500 adults with obesity for 72 weeks. The results are often summarised as a single weight-loss figure, but the timeline inside those results matters just as much. Weight loss was not linear throughout. Most people lost weight most rapidly in the first six months, after which the rate slowed as the body approached a new lower set point.

By week 72, participants taking the highest dose had lost an average of around 20–21% of body weight, but a substantial share of that had happened by week 36. The second half of the trial was less about losing and more about consolidating. That distinction is clinically useful: it tells prescribers that a slower pace after the first six months is not a sign that treatment has stopped working, and it explains why duration needs to be measured in years rather than months.

Tirzepatide is a dual GIP and GLP-1 receptor agonist, it works on appetite, fullness signals and gastric emptying. Those mechanisms are active only while the medicine is being taken. If you want a thorough answer to how long you should take tirzepatide, including what the evidence says about short-term versus extended use, that page brings together the key clinical considerations in one place. That biological reality underpins most of what we know about how long treatment should last, and it is why the question of stopping is taken seriously.

What the six-month checkpoint in NICE guidance means for you

NICE's appraisal of tirzepatide (TA1026) includes a practical checkpoint: if someone has not lost at least 5% of their starting weight after six months at the highest tolerated dose, the prescriber should review whether continuing makes sense. This is not a punishment clause, it is a proportionality test. For the large majority of people who do respond, the guidance simply does not set a ceiling on duration.

Private prescribing follows the licensed indication rather than the NHS-specific eligibility criteria, which means your prescriber is not bound by the same access thresholds that govern NHS cohorts. What they are bound by is clinical judgement: your weight trajectory, how you are tolerating the medicine, any changes in your health, and your own goals. A review before every repeat order is part of how responsible prescribing works.

If you are curious about the cost side of ongoing treatment, the Mounjaro cost page explains how private pricing works and what a legitimate single price includes. Duration questions and cost questions are often asked together, and they deserve equally clear answers.

What happens to weight when people stop tirzepatide

This is the part of the duration question that tends to surprise people. Evidence from GLP-1 trials consistently shows that when the medicine stops, appetite and hunger signals largely return to their pre-treatment baseline. In the SURMOUNT extension data and in semaglutide withdrawal studies, participants who stopped regained a meaningful proportion of lost weight within a year of discontinuing.

That is not a flaw in how the medicine works, it reflects the underlying biology of weight regulation. Obesity is a chronic condition with persistent biological drivers, not a short course of treatment with a fixed end point. The NHS obesity overview explains this framing clearly: the factors that sustain excess weight do not simply reset after treatment ends.

For some people, stopping is planned and supported, for example, after reaching a stable lower weight and building sustainable habits. For others, long-term continuation is the right clinical choice. Some people find they can taper to a lower maintenance dose with their prescriber, and our guidance on how long you should stay on Mounjaro explores exactly those scenarios in detail. There is no single correct answer, and the question of when Mounjaro starts working and the question of when to stop are connected: understanding the timeline helps you plan realistically from the outset.

How a prescriber approaches the duration conversation in practice

At every clinical review, the relevant questions are practical ones: Is your weight continuing to move in the right direction, or has it stabilised at a healthy level? Are you tolerating the current dose? Has anything changed in your health that affects the benefit-to-risk balance? These reviews are not bureaucratic hurdles, they are the mechanism through which duration is calibrated to you specifically.

The detail on how long tirzepatide can be taken covers the regulatory and safety dimensions of long-term use, and is worth reading alongside this page. For those specifically on Mounjaro who want clarity on timing from a clinical perspective, our page on how long you should take Mounjaro addresses the same questions through the lens of real prescribing practice. What the evidence and guidance together suggest is that there is no arbitrary cut-off: treatment continues as long as it is clinically appropriate, well-tolerated and helping you maintain meaningful health benefits.

Our clinical team reviews every repeat order individually, not as a formality, but as the mechanism that keeps duration decisions genuinely personalised. If you have been on treatment for a while and are wondering where you go from here, that conversation starts at the consultation, not at the end of a course. When you are ready to think about eligibility or next steps, you can check your eligibility with our prescribers, your notes, your current dose and your goals all come into that review.